Inositol administration reduces oxidative stress in erythrocytes of patients with  polycistic ovary syndrome. by G. Donà et al.
European Journal of Endocrinology (2012) 166 703–710 ISSN 0804-4643CLINICAL STUDY
Inositol administration reduces oxidative stress in erythrocytes
of patients with polycystic ovary syndrome
Gabriella Dona`, Chiara Sabbadin1, Cristina Fiore1, Marcantonio Bragadin2, Francesco L Giorgino3,
Eugenio Ragazzi4, Giulio Clari, Luciana Bordin* and Decio Armanini1,*
Department of Biological Chemistry, University of Padua, Viale G. Colombo 3, 35131 Padua, Italy, 1Endocrinology Unit, Department of Medical and
Surgical Sciences, University of Padua, Via Ospedale 105, 35128 Padua, Italy, 2Department of Environmental Sciences, University of Venice, Venice, Italy,
3Associazione Ginecologi Extra Ospedalieri (A.G.E.O.), Padua, Italy and 4Department of Pharmacology and Anesthesiology, University of Padua, Padua,
Italy
(Correspondence should be addressed to L Bordin; Email: luciana.bordin@unipd.it; D Armanini; Email: decio.armanini@unipd.it)
*(L Bordin and D Armanini contributed equally to this work)q 2012 European Society of EAbstract
Objective: Possibly due to a deficiency of insulin mediators, polycystic ovary syndrome (PCOS) is
often associated with insulin resistance (IR) and hyperinsulinemia, likely responsible for an elevated
production of reactive oxygen species. We investigated oxidative-related alterations in erythrocytes
and anti-inflammatory effects of inositol in women with PCOS before and after treatment with
myo-inositol (MYO).
Methods: Twenty-six normal-weight PCOS patients were investigated before and after MYO
administration (1200 mg/day for 12 weeks; nZ18) or placebo (nZ8) by evaluating serum
testosterone, serum androstenedione, fasting serum insulin, fasting serum glucose, insulin area
under the curve (AUC), and glucose AUC after oral glucose tolerance test and homeostasis model of
assessment–IR. In erythrocytes, band 3 tyrosine phosphorylation (Tyr-P) level, glutathione (GSH)
content, and glutathionylated proteins (GSSP) were also assessed.
Results: Data show that PCOS patients’ erythrocytes underwent oxidative stress as indicated by band 3
Tyr-P values, reduced cytosolic GSH content, and increased membrane protein glutathionylation.
MYO treatment significantly improved metabolic and biochemical parameters. Significant reductions
were found in IR and serum values of androstenedione and testosterone. A significant association
between band 3 Tyr-P levels and insulin AUC was found at baseline but disappeared after MYO
treatment, while a correlation between band 3 Tyr-P and testosterone levels was detected both before
and after MYO treatment.
Conclusions: PCOS patients suffer from a systemic inflammatory status that induces erythrocyte
membrane alterations. Treatment with MYO is effective in reducing hormonal, metabolic, and
oxidative abnormalities in PCOS patients by improving IR.
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Polycystic ovary syndrome (PCOS) is one of the
most common endocrine–metabolic diseases, affecting
6–10% of women of reproductive age (1). It is
characterized by hyperandrogenism, hirsutism, and
oligo- or anovulation. Increasing evidence supports
the central role of insulin resistance (IR) and
compensatory hyperinsulinemia in the pathogenesis of
the syndrome (2) and in patients’ increased risk of
developing dyslipidemia, hypertension, impaired glu-
cose tolerance, type 2 diabetes mellitus, and cardiovas-
cular disease (3). Some actions of insulin may involve
low-molecular weight inositol phosphoglycan (IPG)
mediators (also known as putative insulin mediators
or second messengers) (4, 5) and several pieces ofndocrinologyevidence suggest that a deficiency in a specific D-chyro
inositol (DCI)-containing IPG (6, 7, 8) and/or altered
DCI metabolism may contribute to IR (9, 10). Previous
studies have shown that oral administration of DCI to
women with PCOS increases the action of insulin,
improving ovulatory function and decreasing blood
pressure, and serum androgen and plasma triglyceride
concentrations (9, 10).
Oxidative stress (OS) is involved in the pathogenesis
and future complications of PCOS. This condition
occurs when reactive oxygen species (ROS), which are
intermediaries of a normal oxygen metabolism, are
produced faster than the endogenous antioxidant
defense systems can neutralize. Previous studies
have demonstrated that hyperglycemia increases
ROS generation from peripheral blood leukocytes (11).DOI: 10.1530/EJE-11-0840
Online version via www.eje-online.org
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state that induces IR and hyperandrogenism in women
with this disorder (12) and also increases the risk of
cardiovascular disease (13).
Many proteins are susceptible to attack by ROS,
especially as sulfhydryl groups are among the most
easily oxidized protein residues. Oxidation can lead to
inter- and/or intramolecular cross-linking, thus indu-
cing protein degradation (14, 15), clustering (16, 17,
18), and enzyme inactivation (18, 19).
We recently demonstrated that diamide-treated
erythrocytes express a well-defined tyrosine phosphoryl-
ation (Tyr-P) level of membrane proteins, particularly of
band 3 (20). Alterations in band 3 Tyr-P levels represent
preexisting modifications of membrane status, like that
observed in glucose-6-phosphate dehydrogenase
(G6PD)-deficient patients (18, 21) suffering from
chronic impairment of antioxidant defenses or in
endometriotic women (22) with systemic inflammation.
Diamide, a mild oxidant, affects the sulfhydryl groups of
cysteines by inducing disulfide bond formation and
triggers band 3 Tyr-P (16, 17, 18, 20, 21, 22), which is a
useful parameter in the evaluation of oxidation-related
damage to cells (18, 21, 22). We also observed that,
while diamide treatment reduced total glutathione
(GSH) contents detectable in the cytosol of endometriotic
patients, normal subjects were unaffected, and the
differences between GSH content before and after
diamide treatment were defined as DGSH, an additional
parameter of inflammatory status in endometriosis (22).
The aim of this study was to evaluate any effects on
clinical, hormonal, and glucose metabolism parameters
in PCOS patients before and after 12 weeks of inositol
dietary supplement. We used myo-inositol (MYO)
because it is widely distributed in nature (23) and
commercially available, whereas DCI, the product of
oxidoreductive epimerization of the carbon 1 hydroxyl
group of MYO, is relatively rare and present in plants
and seeds (24).
In addition, in order to evaluate the inositol effects on
erythrocyte membrane functionality and cell redox
status, we determined diamide-related band 3 Tyr-P
levels and contents of both GSH and membrane
glutathionylated proteins in patients’ erythrocytes.Materials and methods
Materials
Reagents were purchased from Sigma, and anti-
phosphotyrosine (P-Tyr; PY20) mouse MAB was
obtained from Biosource–Invitrogen (Camarillo, CA,
USA). The protease inhibitor cocktail and anti-actin
mouse MAB came from Calbiochem (Darmstadt,
Germany). Antimouse secondary antibody conjugated
with HRP came from Bio-Rad Laboratories. MYO was
purchased from Progine (Firenze, Italy).www.eje-online.orgTestosterone was measured by electrochemilumines-
cence immunoassay (ECLIA) using commercially
available kits (Roche Diagnostics GmbH); 17-OH pro-
gesterone was measured by a solid-phase ELISA using
commercially available kits (DRG Instruments
GmbH, Marburg, Germany); androstenedione was
measured by a solid-phase, competitive chemi-
luminescent enzyme immunoassay using commercially
available kits (Siemens Healthcare Diagnostics Products
Ltd., Llanberis, Gwynedd, UK). The intra-assay and
interassay coefficients of variation were!9%.
Serum glucose levels were measured enzymatically
with glucose hexokinase kit (Roche Diagnostics), and
serum insulin levels were measured by ECLIA (Roche)
with Immulite 2000 DPC Siemens Analyzer.Study protocol
Twenty-six women with PCOS, between the ages of 22
and 30 years, were enrolled at the Department of
Medical and Surgical Sciences of the University of
Padova, Italy. Diagnosis of PCOS was defined when two
of the following criteria were fulfilled: oligo- and/or
anovulation (%8 menstrual periods in the previous
year), clinical and/or biochemical signs of hyperandro-
genism, polycystic ovaries, and exclusion of other
etiologies (25). Exclusion criteria included pregnancy,
body mass index (BMI) O25 kg/m2, hyperprolactine-
mia, thyroid dysfunction, Cushing’s syndrome, and
late-onset adrenal hyperplasia. None of the women
had diabetes or had taken oral contraceptives, anti-
inflammatory drugs, or other hormonal drugs during
the previous 3 months. This study was approved by the
Ethics Committee for Research and Clinical Trials of our
University and all the patients gave their written
informed consent.
At the time of entry into the study, all patients had
serum progesterone concentrations below 2.5 ng/ml.
On the first day of the study (baseline, T0), after a 12 h
overnight fast, blood samples were collected to measure
serum testosterone, androstenedione, glucose, and
insulin.
A citrated blood sample was collected from each
subject to evaluate Tyr-P levels and assess GSH and
glutathionylated proteins (GSSP).
A 2 h oral glucose tolerance test (OGTT) with 75 g
glucose was carried out. Blood samples were collected
after 15, 30, 60, 90, and 120 min to determine serum
glucose and insulin; values are expressed as the area
under the curve (AUC) of glucose and insulin. Index
of IR was a peak of serum insulin value O70 mU/l
during OGTT.
Homeostasis model of assessment–IR (HOMA-IR) was
also used, according to (26). During the same
examination, anthropometric (weight, height, and
BMI) and clinical (Ferriman–Gallwey score, heart rate,
and systolic and diastolic blood pressure) measurements
were taken for all subjects.
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receive MYO dietary supplement powder 1200 mg/day
(nZ18) or matched placebo powder (nZ8) for 12 weeks.
To avoid selection bias, patients were randomized to each
group (treatment or placebo) using a randomly generated
list with the Excel ‘Rand()’ function. In the MYO group,
a larger number of patients were set ‘a priori’ in order to
be more confident with the results and to avoid any
possible distortion due to the variability in pharma-
cokinetics of the substance and to the variable ranges of
dietary inositol assumption.
Administration was from predosed sachets
containing the daily dose; the powder was dissolved in
water before oral intake once a day. Subjects were
instructed not to change their eating habits, activity
level, or lifestyle during the study. At the end of the
study, the measurements and tests performed at base-
line were repeated (posttreatment time, T1).Treatment of erythrocytes
Red blood cells (RBC) were pelleted at 750 g for 3 min.
After removal of supernatant, packed RBC were washed
three times at 750 g for 3 min in five volumes of
Dulbecco’s PBS (D-PBS) to avoid contamination by
leucocytes and platelets. Packed cells (50 ml) were
resuspended (at 20% hematocrit) in D-PBS and
treated at 35 8C for 30 min in the absence (Basal) or
presence (Diamide) of 1.5 mM diamide (dissolved in
D-PBS) (22).
Samples were then centrifuged and packed cells were
washed in D-PBS, and they underwent hemolysis in
1.5 ml hypotonic buffer (5 mM sodium phosphate, pH
8, 0.02% sodium azide (NaN3), 30 mM phenylmethyl-
sulfonyl fluoride, 1 mM sodium orthovanadate, and a
protease inhibitor cocktail).
Membranes were separated from the cytosol by
centrifugation (16 100 g for 20 min in an Eppendorf
centrifuge) and washed once in hypotonic buffer. Aliquots
of membranes (10 mg) were suspected to SDS–PAGE (10%
gels), transferred to nitrocellulose membranes, and
immunostained first with anti-P-Tyr antibody and then
with anti-actin sample loading controls.
Band 3 Tyr-P levels were evaluated densitometrically.
The Tyr-P value of diamide-treated erythrocytes from
PCOS patients before (T0) and after (T1) MYO/placebo
treatment was calculated as the ratio to the Tyr-P level
of diamide-treated erythrocytes obtained in healthy
controls (chosen as arbitrary comparison unit,
experimentally determined as 0.98G0.065, mean
valueGS.D.). To express a standardized measure of
Tyr-P variation after treatment (defined as the Tyr-P
variation index, Vi(Tyr-P)) with respect to baseline value,
the following formula was used:
ViðTyrPÞZ1K
Tyr  PT1
Tyr  PT0
 
:Determination of GSH and GSSP in
erythrocytes
Total GSH was determined according to the Tietze
method (27). Briefly, 10 ml cytosol obtained from
differently treated erythrocytes were added to 2 ml
reaction mixture containing 1.9 ml phosphate
0.1 M/EDTA 0.6 mM buffer, pH 7.4, 30 ml 5,5 0-dithio-
bis(2-nitrobenzoic acid) 10 mM, 100 ml NADPH 5 mM,
and 10 mg glutathione reductase and analyzed spectro-
photometrically at 412 nm. The decrease in total GSH
content after diamide treatment (DGSH) was expressed
as 1KGSH(Diamide)/GSH(Basal) (22).
A variation index for DGSH (Vi(DGSH)) was calculated,
as for Tyr-P, according to the following formula:
ViðDGSHÞZ1K
DGSHT1
DGSHT0
 
:
GSSP was determined according to (28). Briefly,
membranes, obtained as described above, were depro-
teinized by adding trichloroacetic acid (TCA; 5% final
concentration). After centrifugation for 3 min, a
16 100 g acid-precipitated membrane protein prep-
aration was resuspended and brought to pH 12,
which induces GSH release from proteins via a
cysteine-reduced/oxidized (SH/SS) exchange. The
reaction was stopped by adding TCA (5% final
concentration); the amount of released GSH was
determined enzymatically in the supernatants of
centrifuged samples.
The increase in GSH released from membranes of
erythrocytes treated with diamide, which was repre-
sentative of the increase in glutathionylated protein
content (DGSSP), was expressed as (GSH(Diamide)/
GSH(Basal))K1.
Also here, a variation index for DGSSP (Vi(DGSSP)) was
calculated, according to the following formula:
ViðDGSSPÞZ1K
DGSSPT1
DGSSPT0
 
:Statistical analysis
Data are expressed as meanGS.D. Comparisons were
obtained with Student’s t-test for paired or unpaired
data, as appropriate. Statistical significance was set at
P!0.05 (two tailed). Any relationships between pairs of
variables were tested by least-squares linear regression.
Pearson’s correlation coefficient r was used to quantify
the strength of the relationships. The statistical
significance of r was determined by ANOVA; a P value
of !0.05 was considered statistically significant (two
tailed). Comparison between regression lines was
performed with ANOVA on slope and intercept
parameters.www.eje-online.org
Table 1 Baseline clinical characteristics and hematochemical parameters of two groups of PCOS patients. Data are
meanGS.D. Normal values for serum testosterone and androstenedione and insulin and glucose AUC were calculated in a
group of healthy women (nZ15): average age, 23.6G1.5; weight, 57.9G4.6; and BMI, 21.4G1.2.
Parameters Normal range MYO group (nZ18) Placebo group (nZ8) P a
Age (years) – 23.5G2.1 23.6G1.4 6.1257
Weight (kg) – 58.9G6.4 58.8G3.5 6.6347
BMI (kg/m2) – 21.6G1.9 21.9G0.6 4.3354
Blood pressure (mmHg)
Systolic !120 117.2G10.7 112.5G7.1 1.8653
Diastolic !80 72.2G4.3 71.3G3.5 4.0257
Serum testosterone (nmol/l) 0–8G0–2 1.77G0.50 1.96G0.25 2.1701
Serum androstenedione (nmol/l) 7.5G1–9 14.99G3.51 14.34G2.13 4.3972
Fasting serum insulin (mU/l) 5–20 7.49G4.44 6.75G1.67 4.5354
Fasting serum glucose (mmol/l) 3.7–6.0 4.79G0.32 4.73G0.38 4.5910
Insulin AUC (mU/l per min) 2467.34G654.45 6989.47G2301.69 7499.38G2047.60 4.1354
Glucose AUC (mmol/l per min) 729.23G37.25 712.06G76.71 700.12G46.61 4.7840
HOMA-IR !2.5 1.60G0.99 1.40G0.40 4.0625
aStatistical analysis was obtained with Student’s t-test between the two groups.
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Baseline clinical characteristics and hematochemical
parameters determined in the two groups of PCOS
showed no significant differences (Table 1).
Following the 12-week treatment, the studied
parameters in the MYO group showed significant
decreases with respect to baseline (Table 2). Conversely,
in the placebo group, no significant change was found
at the end of the treatment, except for an increase in
insulin-related metabolic parameters (Table 2).
This slight worsening of insulin AUC in the placebo
group is probably due to the fact that patients were not
treated for a few months before and during the study.
This is a further demonstration that inositol improves
metabolic patterns even after 3 months.
Comparing the two groups, significant differences
were observed in BMI, serum testosterone, serumTable 2 Changes in clinical characteristics and hematochem
12 weeks in PCOS patients. Data are meanGS.D. of paired differ
indicates a decrease after treatment in comparison with baselin
Parameters MYO group (nZ18)
Weight (kg) K1.83G1.86c
BMI (kg/m2) K0.69G0.69c
Blood pressure (mmHg)
Systolic K3.3G5.9c
Diastolic C0.6G2.4
Serum testosterone (nmol/l) K0.35G0.24c
Serum androstenedione (nmol/l) K3.96G2.16c
Fasting serum insulin (mU/l) K2.33G2.61c
Fasting serum glucose (mmol/l) K0.14G0.31
Insulin AUC (mU/l per min) K1668.08G1388.52c
Glucose AUC (mmol/l per min) K13.42G65.52
HOMA-IR K0.54G0.62c
aComparison between groups; statistical analysis with Student’s t-test.
bThe effect size was calculated post-hoc according to Cohen’s d formula (4
is considered a ‘small’ effect; around 0.5, a ‘medium’ effect; and O0.8, a
cStatistically significant variation between times T1 and T0 within patient
Student’s t-test.
www.eje-online.organdrostenedione, fasting serum insulin, insulin AUC
after OGTT, and HOMA-IR (Table 2).
To examine RBC membrane status, diamide-related
band 3 Tyr-P levels were determined in patients’
erythrocytes. Although in the absence of diamide
stimulation Tyr-P could not be detected in erythrocytes
from either patients or controls (data not shown), when
PCOS RBC were incubated with diamide, membranes
showed higher band 3 Tyr-P levels in comparison with
RBC from healthy subjects (Table 3, see footnote).
Comparing RBC from PCOS patients at the two time
points T0 (baseline) and T1 (following MYO treatment)
shows that Tyr-P levels were significantly affected by
MYO treatment (Table 3, P!0.0001). No variations
were found in the placebo-treated group (Table 3).
The antioxidant condition of RBC was also evaluated
by measuring changes in GSH cellular content (22).
As shown in Table 3, the decrease in GSH (DGSH) wasical parameters after administration of MYO or placebo for
ences between times T1 and T0 for each patient. Negative sign
e.
Placebo group (nZ8) P a Effect sizeb
C0.25G0.71 0.0055 1.34
C0.09G0.27 0.0058 1.35
C1.3G6.4 0.0888 0.79
C2.5G4.6 0.1645 0.62
K0.01G0.29 0.0043 1.38
C0.28G0.39 !0.0001 2.41
C1.00G0.76c 0.0018 1.55
C0.06G0.13 0.0816 0.077
C347.38G314.98c 0.0005 1.77
C17.06G28.64 0.2224 0.55
C0.26G0.16c 0.0015 1.57
8), using pooled S.D.s. According to Cohen’s d, an effect size of 0.2–0.3
‘large’ effect.
groups (P!0.05 as significance limit); statistical analysis with paired
Table 3 Comparison between the parameters investigated in
erythrocytes from PCOS patients in MYO and placebo groups.
Data are meanGS.D. calculated according to the formula in the
Materials and methods section. Tyr-P value of diamide-treated
erythrocytes from PCOS patients before (T0) and after (T1)
MYO/placebo treatment, calculated as ratio to Tyr-P level of
diamide-treated erythrocytes obtained in healthy controls (chosen
as arbitrary comparison unit, experimentally determined as
0.98G0.065, mean valueGS.D.).
Parameters
MYO
group
(nZ18)
Placebo
group
(nZ8) P a
Effect
sizeb
Tyr-P
T0 2.06G0.28 2.00G0.24 0.5819 0.23
T1 1.36G0.30
c 2.01G0.27 !0.0001 2.32
Vi(Tyr-P) 0.34G0.10 K0.01G0.05 !0.0001 4.12
DGSH
T0 0.38G0.04 0.39G0.03 0.5290 0.28
T1 0.23G0.06
c 0.40G0.02 !0.0001 3.43
Vi(DGSH) 0.40G0.14 K0.02G0.05 !0.0001 3.62
DGSSP
T0 0.33G0.03 0.32G0.02 0.3695 0.38
T1 0.17G0.04
c 0.31G0.03 !0.0001 3.90
Vi(DGSSP) 0.48G0.11 0.02G0.07 !0.0001 4.79
DGSH, decrease in cytosol glutathione content after diamide treatment,
expressed as 1KGSH(Diamide)/GSH(Basal); DGSSP, increase in glutathiony-
lated proteins after diamide treatment, expressed as the increase in
glutathione released from membrane proteins or (GSH(Diamide)/GSH(Basal))K1.
aP value following Student’s t-test, comparison between MYO and placebo
groups.
bThe effect size was calculated post-hoc according to Cohen’s d formula (48),
using pooled S.D.s. According to Cohen’s d, an effect size of 0.2–0.3 is
considered a ‘small’ effect; around 0.5, a ‘medium’ effect; andO0.8, a ‘large’
effect.
cP!0.0001, paired Student’s t-test, comparison between T1 and T0 within
each group.
Table 4 Correlation between hormonal/metabolic parameters and
Tyr-P levels in erythrocytes before (T0) and after (T1) myo-inositol
administration (nZ18).
Pearson’s correlation
coefficient r
Tyr-P vs T0 T1
Serum testosterone (nmol/l) 0.5698* 0.4943*
Serum androstenedione (nmol/l) 0.2028 K0.1447
Fasting serum insulin (mU/l) 0.3264 0.2756
Fasting serum glucose (mmol/l) K0.2193 0.0320
Insulin AUC (mU/l per min) 0.5032* 0.1673
Glucose AUC (mmol/l per min) K0.2076 K0.3208
HOMA-IR 0.2968 0.2913
*P!0.05; statistical analysis of regression by ANOVA.
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with MYO; no changes were detected in control
patients.
Treatment with dietary MYO also prevented any
increase in glutathionylated protein content (DGSSP) in
erythrocytes from PCOS patients, the variation being
even lower at T1 compared with T0 (P!0.0001);
conversely, no variation occurred in the placebo group
(Table 3).
The variation indices Vi (see Materials and methods
section) of the three parameters of RBC membrane-
oxidative status allow for a direct unbiased comparison
of Tyr-P, GSH, and GSSP changes occurring in the two
groups of patients (Table 3). All three parameters were
significantly different in MYO and placebo groups
(P!0.0001).
To assess interrelationships between RBC parameters
and hormonal/metabolic data obtained in blood from
patients at the two time points, before and after MYO
treatment, a linear regression was performed and the
strength of correlation was assessed by Pearson’s
correlation coefficient r (Table 4).
The main result obtained was the significant
correlation between serum testosterone and Tyr-P levels(P!0.05). The link between Tyr-P and testosterone
levels before and after MYO treatment is shown in Fig. 1.
Comparison of the two regression lines, at T0 and T1,
revealed a significant difference between the intercepts
in MYO-treated patients (P!0.0001); the slope
remained the same, indicating that, although phos-
phorylation kinetic mechanisms were unaffected by
MYO administration, they were quantitatively reduced.
The same analysis applied to the placebo-treated group
confirming the significant correlation between erythro-
cyte Tyr-P and serum testosterone levels at baseline
(PZ0.0032; data not shown).
A significant correlation was also detected between
insulin AUC and Tyr-P, but only before treatment
(Table 4). After MYO treatment, the concomitant
reduction found for Tyr-P and insulin AUC values
produced a clustering of data that abolished the
regression of the two variables.Discussion
A common misconception related to PCOS is that every
patient is overweight, but this is not always the case,
because some of the women diagnosed with this
condition are of normal weight (29). In this study, we
show that IR can be present in PCOS with normal BMI,
confirming that IR is not merely linked to obesity but
also to a genetic or epigenetic situation (30, 31, 32, 33).
An increase in the generation of ROS by peripheral
blood leucocytes in response to acute hyperglycemia has
been previously demonstrated in PCOS patients (11),
and the finding that physiological and pharmacological
insulin infusions in vivo or in vitro revealed the oxidative
effect of insulin (32, 33, 34, 35, 36) raised the hypothesis
of systemic redox impairment in such patients.
Our results show that this redox impairment is
effectively systemic, as indicated by oxidative-related
alterations in the erythrocytes of all patients. In
addition, insulin AUC significantly correlated with RBC
alterations in patients, rather than fasting glucose and
fasting insulin or glucose AUC. The values of the lastwww.eje-online.org
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Figure 1 Linear regression between erythrocyte Tyr-P values and
testosterone serum levels in MYO group before (T0) and after (T1)
treatment. ANOVA indicated a significant difference (P!0.0001)
between intercepts of regression lines in MYO-treated patients.
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healthy women, thus corroborating the oxidative effect
of insulin rather than that of hyperglycemia (Table 1).
We have recently demonstrated that enhanced ROS
production in endometriotic patients is correlated with
both increased diamide-induced erythrocyte band 3
Tyr-P level and high DGSH, indicating that OS induces
structural modifications of membranes (22). Diamide-
induced OS in human erythrocytes causes net mem-
brane rearrangement with band 3 aggregate formation
(16, 18) and kinase (37) and phosphatase (38)
recruitments, all leading to a triggering of band 3
Tyr-P levels (20). In PCOS, RBC are much more sensitive
to diamide treatment and, consequently, band 3 Tyr-P
reaches levels two or three times higher than those of
controls, probably due to an altered redox system,
predisposing membrane proteins to be more markedly
oxidized. This was further confirmed by the observation
that total cell GSH did not differ from that of healthy
controls (data not shown) but that, once RBC are
incubated with diamide, patients’ GSH contents are far
lower, with DGSH ranging from 0.38G0.04 (Table 3).
By contrast, when membranes were extracted and
analyzed for their contents of glutathionylated proteins
(GSSP), glutathionylation after diamide treatment
increased drastically in PCOS RBC (DGSSP, 0.33
G0.03; Table 3) but not in healthy controls (data not
shown). Taken together, these results show that PCOS
RBC are subjected to OS, which induces membrane
oxidative status alterations.
Interestingly, MYO treatment positively affected the
oxidative status of RBC, as shown by the partial
restoration of GSH contents (decreased DGSH) and the
reduction of both band 3 Tyr-P levels and protein
glutathionylation (decreased DGSSP). The presentwww.eje-online.orginvestigation shows that even a low dose of MYO
administered for 3 months yields therapeutically
appreciable effects. In fact, clinical ameliorations were
achieved although the posology of 1200 mg/day was
almost one-fourth of that commonly used for MYO (39,
40) and similar to that for DCI (6). In addition, as an
anecdotal finding, one of the patients enrolled in the
MYO group continued the intake of half a dose of MYO
(i.e. 600 mg/day) after the end of the study period, and
the clinical symptoms appeared again (data not shown).
This would suggest that the dose used in our study may
represent the lowest range of a posology aimed at
obtaining an appreciable effect in PCOS patients.
This study has also evaluated the hormonal and
metabolic status of PCOS patients, and compared values
at T0 and T1, to analyze the effect of MYO treatment on
clinical parameters.
Our findings confirm that oral MYO administration
significantly decreases testosterone, androstenedione,
fasting serum insulin, insulin AUC levels, and HOMA-IR.
Two different pathways may depend on MYO:
phosphoinositide-related signal transduction and insu-
lin-related metabolic response. In the first pathway,
MYO, synthesized from glucose 6-phosphate, carried
into the cell from plasma or obtained by a recycling of
intracellular inositol 1,4,5-triphosphate, is incorporated
into activated phosphatidic acid to constitute membrane
phosphatidylinositols (PI) (40, 41, 42, 43). In the second
pathway, either MYO or its epimerase-converted (39)
chiro isoform DCI (44, 45) constitutes IPGs (4), which
are released from cell membrane glycosylphosphatidy-
linositols in response to insulin. Once released, IPGs can
affect any tissues and cells implicated in insulin action
(45), thus potentiating insulin effects (46).
The significant reduction of Tyr-P levels in RBC found
after MYO treatment and the reduction in insulin AUC
confirm that this kind of therapy can improve IR, one of
the typical features of PCOS (10). In fact, dietary MYO
uptake can affect membrane composition both directly,
by increasing intracellular PI contents and/or PI-related
pathways, and indirectly, by modulating the OS induced
by the inappropriate hyperinsulinemic response linked
to IR.
Another novel finding is the significant correlation
between Tyr-P and testosterone levels at T0 and, more
interestingly, at T1 (Table 4), as shown by a comparison
of the two regression lines (Fig. 1). The significant
difference between the intercepts of the two lines in
MYO-treated patients (P!0.0001) suggests that altera-
tion of the phosphorylation process of erythrocyte band
3 is mediated by higher testosterone levels in serum. We
hypothesize that administration of MYO (but not of
placebo) improves band 3 Tyr-P (and related DGSH and
DGSSP) through a decrease in testosterone levels, thus
supporting the MYO-related insulin messenger pathway.
In conclusion, PCOS patients suffer from a systemic
inflammatory status, as shown by the increased
erythrocyte response to diamide-induced OS, with
Inositol reduces oxidative stress in PCOS 709EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012) 166increases in Tyr-P level, DGSH, and DGSSP parameters,
which significantly correlate with testosterone levels.
The use of MYO, even at 1200 mg/day, reduced
inflammatory status and IR-related hyperinsulinemia
(10, 47).
Further studies investigating both the intracellular
mechanism triggered by inositol and the extracellular
inositol-related IPG pathways are warranted to better
define how MYO could improve insulin response and
oxidative status in patients with PCOS. The Tyr-P
process could be very useful in monitoring patients’
conditions and in choosing an adequate therapy for IR.
In addition, MYO could be proposed as an alternative to
metformin treatment because the former can affect
insulin target tissues and cells and potentiate insulin
effects without the side effects of metformin.Declaration of interest
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